David P Hochman

David P Hochman purchased 5,000 shares of OBIO at $3.83; stock now down 27.9% from 52-week high as company burns cash amid growth.

David P Hochman purchased 5,000 shares at $3.83, increasing his total holdings to 1.06M shares, a modest 0.5% addition to his existing position. His cross-ticker track record shows weak timing discipline (21.43% 90-day win rate with average 90d return of +3.6%), and at OBIO specifically, he has mixed results: 3 of 5 prior buys posted positive 90-day returns, but his most recent purchase on 2026-05-15 has yielded only 1.6% gain at the 90-day mark. The company context raises concerns: OBIO is unprofitable with $-20.7M net income in its most recent full fiscal year, revenue of only $110.0K in the latest quarter, and the stock is currently -27.9% from its 52-week high. While the substantial annual revenue growth of +1169.2% appears dramatic, this reflects a very early-stage company with minimal absolute revenue, and the timing of this purchase against current price weakness and ongoing losses warrants scrutiny of whether the insider possesses non-public information or is simply averaging into a distressed position.

Hochman buys 5,000 OBIO shares at $3.77; stock -26.2% from 52-week high, -12.7% in 30 days

David P Hochman purchased 5,000 shares at $3.77 on 2026-05-15, expanding his holdings to 1.06M shares, while OBIO trades -26.2% below its 52-week high of $5.42 and -12.7% over the past 30 days. Among his prior trades at OBIO, timing results are mixed: 2 of 5 prior buys delivered positive 90-day returns, while the most recent buy on 2026-03-13 at an earlier price point returned -3.7% in 30 days and -7.2% over 90 days, suggesting recent buying has not been consistently rewarded. The company faces material headwinds—it reported $110.0K in latest quarterly revenue against a $-20.7M net loss for the most recent full year, though annual revenue growth of +1169.2% indicates recent acceleration from a very small base. The current purchase near depressed price levels warrants monitoring of whether the insider perceives stabilization or whether further deterioration follows.

Hochman bought 5,000 OBIO shares at $4.07 on 2025-11-14; stock up 24.4% in 30 days but insider's cross-ticker timing record weak.

Hochman David P purchased 5,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.07 on 2025-11-14, increasing his holdings to 612.8K shares. OBIO's stock has risen 24.4% over the prior 30 days and 62.0% over 90 days, recovering from a 52-week low of $2.35 toward a range floor following a -33.5% decline from the 52-week high of $6.21. However, Hochman's cross-ticker track record shows modest predictive value: 11 prior buys with an average 90-day return of -2.2% and a 90-day win rate of 10.00%, suggesting his timing has been poor in broader context. At the same ticker (OBIO), his prior trade history is mixed—only 1 of 4 prior buys showed positive 90-day returns, and he acquired shares as recently as 2025-08-21 at a loss. The underlying company remains unprofitable (net income $-20.8M in the latest period) despite the recent share-price appreciation, which warrants scrutiny of whether the rally is sustainable or momentum-driven.

David P Hochman buys 6,000 OBIO shares at $2.49; stock down 61.2% from $6.70 high; 3 other insiders also bought in past 14 days.

Hochman purchased 6,000 shares at $2.49 on 2025-08-21, adding to holdings that now stand at 651.5K shares. The stock is currently trading at $2.60, down 61.2% from its 52-week high of $6.70 and down 21.0% over the past 30 days. Orchestra BioMed is unprofitable with a net income of $-19.4M on revenue of $836.0K (latest quarter), and annual revenue has contracted 4.4% year-over-year. Across his prior 4 measurable buys at this ticker, Hochman has not achieved a single positive 90-day outcome. A cluster pattern is evident: 3 other insiders also bought within the past 14 days. The transaction signals sustained insider acquisition activity despite deteriorating fundamentals and a stock down significantly from its 52-week peak, though prior purchase timing at this specific ticker has not proven predictive of near-term recovery.

Hochman buys 20,000 OBIO shares at $2.75; holdings rise 6.1% to 349,331 shares amid -63.7% 52-week drawdown.

Hochman purchased 20,000 shares at $2.75, increasing his stake by 6.1% to 349,331 shares total, during a period when OBIO trades at $2.68, down 63.7% from its 52-week high of $7.38. At the same ticker, his prior 5 trades across September and December 2024 generated mixed near-term results (30-day range +7.5% to +20.4%) but showed zero well-timed entries at the 90-day mark, with three trades followed by negative 90-day returns ranging from -0.8% to -17.5%. The company remains unprofitable with a latest quarterly revenue of $868.0K and full-year net income of $-18.8M, against a market cap of $102.7M. This purchase occurs against both a near-term headwind (90-day change +10.7%, 30-day change -7.3%) and a fundamental backdrop of declining revenue (-4.4% year-over-year) without offsetting earnings.

Hochman purchases 4,000 OBIO shares at $4.66 on 2024-12-23; stock down -51.8% from 52-week high and trading -16.0% over 30 days.

David P. Hochman acquired 4,000 shares at $4.66, adding to his 579.5K share position. This is his second buy within a week at OBIO (prior purchase on 2024-12-18) amid a deteriorating price environment: the stock has fallen -51.8% from its 52-week high and declined -16.0% over the trailing 30 days. His same-ticker purchase history shows four prior buys in September 2024, none of which posted positive 90-day returns (outcomes ranged from -3.3% to +0.0%), indicating a pattern of accumulation that has not been rewarded by subsequent stock appreciation. Fundamentally, OBIO is unprofitable (net income $-15.4M in the latest quarter), posted declining annual revenue (-21.9% year-over-year), and operates at a $181.3M market cap on minimal revenue ($987.0K latest quarter). The timing and context—rapid back-to-back accumulation during a steep drawdown in an unprofitable, declining-revenue company—merit close monitoring to understand his rationale.

David P Hochman bought 5,000 shares of OBIO at $4.91 on 2024-12-18 (value $24,550.00), now trading 2.2% below entry.

Hochman purchased 5,000 shares at $4.91, adding to an existing position of 570,498 shares. The stock currently trades at $4.80, down 7.2% over 30 days and down 55.1% from its 52-week high of $10.68. Orchestra BioMed is unprofitable with annual revenue declining 21.9% year-over-year and most recent quarterly revenue of just $987,000.00 against a net loss of $15,426,000.00. Hochman's prior trades at OBIO (five purchases on 2024-09-24 and 2024-09-25) showed positive 30-day outcomes ranging from 16.5% to 20.8%, but those outcomes remain incomplete at the 90-day measurement window. The cross-ticker track record shows 0 of 7 prior buys were well-timed at 90 days, with an average 90-day return of -16.9%.

Director Hochman buys 10,000 OBIO shares across 5 trades for $47,905.00 amid -40.7% 90-day decline.

Hochman David P acquired 10,000 shares in 5 separate transactions on 2024-09-24 and 2024-09-25 at a blended average price of $4.79, for a total of $47,905.00. This purchase is noteworthy against the backdrop of significant recent price deterioration: the stock is down 40.7% over the past 90 days and down 54.8% from its 52-week high of $10.68. The company's fundamentals are strained, with quarterly revenue of $778,000.00 and a net loss of $15,980,000.00, plus annual revenue contraction of -21.9%. His prior trades at OBIO show a 0% 90-day win rate (1 of 1 completed trades resulted in a loss), and his cross-ticker track record also shows 0% win rate over 90 days despite a modest 30-day average of +7.8%. The post-transaction holding of 2,000 shares reflects a net addition of 10,000 shares from a pre-transaction short position of -8,000 shares, indicating a significant shift in his exposure to the company.

David P Hochman purchases 2,500 shares of OBIO at $5.84 (Aug 14), now trading -43.7% from 52-week high.

Hochman bought 2,500 shares at $5.84 on 2024-08-14, adding to existing holdings of 565,498 shares. The transaction occurred when the stock was already deeply depressed relative to its 52-week high of $10.77, trading at -43.7% from that peak and down 28.8% over the prior 30 days. The company reported minimal quarterly revenue of $778,000.00 and a net loss of $-15,980,000.00, with annual revenue contraction of -21.9% year-over-year, indicating fundamental operational strain. Hochman's prior buy at this same ticker on 2024-06-25 has shown 30-day gains of 16.0%, though longer-term validation is not yet available. The open-market purchase adds incremental evidence of insider participation during a period of material price weakness and reported losses, though the small position increase (+0.4% of pre-transaction holdings) limits the signal strength.

Hochman bought 1,000 shares of OBIO at $6.95; company logged $-13.5M net loss last quarter and -21.9% revenue decline YoY.

Hochman David P purchased 1,000 shares at $6.95 on 2024-06-25, bringing his holdings to 333,502 shares. The transaction is modest in scale relative to his existing position (a +0.3% increase) and modest in dollar terms ($6,950.00). The purchase occurred in a context of material operational stress: the latest quarter showed revenue of $620,000.00 against a net loss of $-13,463,000.00, and the company reported annual revenue decline of -21.9% versus the prior fiscal year. The stock has since recovered 29.4% over 30 days and 30.2% over 90 days from the transaction date, though it remains -36.3% below its 52-week high. The small size and the company's persistent unprofitability do not establish a clear signal of insider conviction about near-term recovery.